Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome - Archive ouverte HAL Access content directly
Journal Articles Molecular Therapy - Methods and Clinical Development Year : 2019

Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome

(1, 2) , (3) , (1, 2) , (4) , (5) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (1, 2) , (4) , (3) , (1, 2) , (1, 2) , (1, 2)
1
2
3
4
5

Abstract

Adeno-associated viruses (AAVs) are among the most efficient vectors for liver gene therapy. Results obtained in the first hemophilia clinical trials demonstrated the long-term efficacy of this approach in humans, showing efficient targeting of hepatocytes with both self-complementary (sc) and single-stranded (ss) AAV vectors. However, to support clinical development of AAV-based gene therapies, efficient and scalable production processes are needed. In an effort to translate to the clinic an approach of AAV-mediated liver gene transfer to treat Crigler-Najjar (CN) syndrome, we developed an (ss)AAV8 vector carrying the human UDP-glucuronosyltransferase family 1-member A1 (hUGT1A1) transgene under the control of a liver-specific promoter. We compared our construct with similar (sc)AAV8 vectors expressing hUGT1A1, showing comparable potency in vitro and in vivo. Conversely, (ss)AAV8-hUGT1A1 vectors showed superior yields and product homogeneity compared with their (sc) counterpart. We then focused our efforts in the scale-up of a manufacturing process of the clinical product (ss)AAV8-hUGT1A1 based on the triple transfection of HEK293 cells grown in suspension. Large-scale production of this vector had characteristics identical to those of small-scale vectors produced in adherent cells. Preclinical studies in animal models of the disease and a good laboratory practice (GLP) toxicology-biodistribution study were also conducted using large-scale preparations of vectors. These studies demonstrated long-term safety and efficacy of gene transfer with (ss)AAV8-hUGT1A1 in relevant animal models of the disease, thus supporting the clinical translation of this gene therapy approach for the treatment of CN syndrome.
Fichier principal
Vignette du fichier
S2329050118301359.pdf (2.72 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02179298 , version 1 (21-10-2021)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Fanny Collaud, Giulia Bortolussi, Laurence Guianvarc'H, Sem Aronson, Thierry Bordet, et al.. Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Molecular Therapy - Methods and Clinical Development, 2019, 12, pp.157-174. ⟨10.1016/j.omtm.2018.12.011⟩. ⟨hal-02179298⟩
141 View
33 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More